Graft type for femoro-popliteal bypass surgery

• Published in: Cochrane database of systematic reviews 2010-05 (5), p.CD001487-CD001487
• Main Authors: Twine, Christopher P, McLain, Alexander D
• Format: Article
• Language: English
• Subjects: Arterial Occlusive Diseases - surgery; Blood Vessel Prosthesis Implantation; Femoral Artery - surgery; Humans; Intermittent Claudication - surgery; Leg - blood supply; Polyethylene Terephthalates; Polytetrafluoroethylene; Popliteal Artery - surgery; Randomized Controlled Trials as Topic; Saphenous Vein - transplantation; Transplantation, Autologous; Umbilical Veins - transplantation; Vascular Surgical Procedures
• ISSN: 1469-493X
• DOI: 10.1002/14651858.CD001487.pub2

Femoro-popliteal bypass is implemented to save limbs that might otherwise require amputation, in patients with ischaemic rest pain or tissue loss; and to improve walking distance in patients with severe life-limiting claudication. Contemporary practice involves using autologous vein, polyterafluoroethylene (PTFE) or Dacron as a bypass conduit.This is an update of a Cochrane review first published in 1999 and previously updated in 2002. The objective of this review was to determine the most effective type of graft for femoro-popliteal bypass surgery. The Cochrane Peripheral Vascular Diseases Group searched their Specialised Register (last searched January 2010) and the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2010, Issue 1 for last search). The authors searched reference lists of relevant articles, and handsearched conference proceedings from the British and European Vascular Surgical Societies. Randomised trials comparing femoro-popliteal grafts. Two authors (CT and ADM) screened studies, extracted data and assessed trials. Thirteen randomised control trials were included with a total of 2313 patients (1955 above knee, 358 below knee bypass surgery). Seven graft types were compared (reversed and in situ autologous vein, PTFE with and without vein cuff, human umbilical vein (HUV), Dacron and heparin bonded Dacron (HBD).Above the knee, there was a benefit in primary patency for autologous vein over PTFE (P = 0.0001) and HUV (P = 0.0003) by 60 months. Dacron showed primary patency benefit over PTFE by 24 months (P = 0.02), continuing to 60 months (P = 0.02). HUV also showed benefit over PTFE by 24 months (P = 0.0003) in one trial. Below the knee, in the one trial there was a significant benefit in primary patency for PTFE with a vein cuff when compared to PTFE alone at all time intervals to 24 months (P = 0.03).Limited data were available for limb survival. Antiplatelet and anticoagulant protocols varied extensively between trials, and in some cases within trials. There was a clear primary patency benefit for autologous vein when compared to synthetic materials for above knee bypasses. In the long term (five years) Dacron confers a small primary patency benefit over PTFE for above knee bypass. PTFE with a vein cuff improved primary patency when compared to PTFE alone for below knee bypasses. Further randomised data is needed to ascertain whether this information translates into improvement in limb survival.